This page details some of the publications generated by research at the Sheffield Kidney Institute. We keep this page updated regularly.

 

  1. Effect of pamidronate on bone loss after kidney transplantation: a randomized trial.
    Walsh SB, Altmann P, Pattison J, Wilkie M, Yaqoob MM, Dudley C, Cockwell P, Sweny P, Banks LM, Hall-Craggs M, Noonan K, Andrews C, Cunningham J.
    Am J Kidney Dis. 2009 May;53(5):856-65.
  2. Impact of Vitamin D Dose on Biochemical Parameters in Patients with Secondary Hyperparathyroidism Receiving Cinacalcet.
    Wilkie M, Pontoriero G, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazão JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Zani VJ, Carter D, Messa P.
    Nephron Clin Pract. 2009 Apr 10;112(1):c41-c50. 
  3. Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients.
    McIntyre CW, Pai P, Warwick G, Wilkie M, Toft AJ, Hutchison AJ.
    Clin J Am Soc Nephrol. 2009 Feb;4(2):401-9. 
  4. Homophilic and heterophilic polycystin 1 interactions regulate E-cadherin recruitment and junction assembly in MDCK cells.
    Streets AJ, Wagner BE, Harris PC, Ward CJ, Ong AC.
    J Cell Sci. 2009 May 1;122(Pt 9):1410-7. 
  5. Inhibition of compensatory renal growth by the N-terminus of a sheep-derived peptide.
    Haylor JL, Parker E, Risbridger GP, Beale D, Brown BL, Dobson PR, Clarke IJ, Hart JE.
    Regul Pept. 2009 Jan 8;152(1-3):48-53. 
  6. Modulation of tissue transglutaminase in tubular epithelial cells alters extracellular matrix levels: a potential mechanism of tissue scarring.
    Fisher M, Jones RA, Huang L, Haylor JL, El Nahas M, Griffin M, Johnson TS.
    Matrix Biol. 2009 Jan;28(1):20-31.
  7. Potential role of growth factors with particular focus on growth hormone and insulin-like growth factor-1 in the management of chronic kidney disease.
    Feldt-Rasmussen B, El Nahas M.
    Semin Nephrol. 2009 Jan;29(1):50-8. 
  8. Encapsulating peritoneal sclerosis: clinical significance and implications.
    Augustine T, Brown PW, Davies SD, Summers AM, Wilkie ME.
    Nephron Clin Pract. 2009;111(2):c149-54
  9. Cardiorenal Risk Prevalence in Sickle Cell Hemoglobinopathy.
    Abo-Zenah H, Moharram M, El Nahas AM.
    Nephron Clin Pract. 2009 Apr 23;112(2)
  10. CKD and poverty: a growing global challenge.
    Hossain MP, Goyder EC, Rigby JE, El Nahas M.
    Am J Kidney Dis. 2009 Jan;53(1):166-74.
  11. Identification and functional characterization of an N-terminal oligomerization domain for polycystin-2.
    Feng S, Okenka GM, Bai CX, Streets AJ, Newby LJ, DeChant BT, Tsiokas L, Obara T, Ong AC.
    J Biol Chem. 2008 Oct 17;283(42):28471-9. 
  12. Activation of TRPP2 through mDia1-dependent voltage gating.
    Bai CX, Kim S, Li WP, Streets AJ, Ong AC, Tsiokas L.
    EMBO J. 2008 May 7;27(9):1345-56. 
  13. Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and treatment.
    Chang MY, Ong AC.
    Nephron Physiol. 2008;108(1):p1-7. Epub 2007 Dec 13. Review.
  14. Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras/Raf signalling system.
    Parker E, Newby LJ, Sharpe CC, Rossetti S, Streets AJ, Harris PC, O'Hare MJ, Ong AC.
    Kidney Int. 2007 Jul;72(2):157-65. Epub 2007 Mar 28.
  15. Involvement of hypoxia-inducible transcription factors in polycystic kidney disease.
    Bernhardt WM, Wiesener MS, Weidemann A, Schmitt R, Weichert W, Lechler P, Campean V, Ong AC, Willam C, Gretz N, Eckardt KU.
    Am J Pathol. 2007 Mar;170(3):830-42.
  16. Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation.
    Hamer RA, Chow CL, Ong AC, McKane WS.
    Transplantation. 2007 Jan 15;83(1):36-40.
  17. Endothelin B receptor blockade accelerates disease progression in a murine model of autosomal dominant polycystic kidney disease.
    Chang MY, Parker E, El Nahas M, Haylor JL, Ong AC.
    J Am Soc Nephrol. 2007 Feb;18(2):560-9.
  18. The epidemic challenge of chronic kidney disease in older patients.
    Abdelhafiz AH, Tan E, El Nahas M.
    Postgrad Med. 2008 Nov;120(4):87-94. Review.
  19. A population-based screening for microalbuminuria among relatives of CKD patients: the Kidney Evaluation and Awareness Program in Sheffield (KEAPS).
    Bello AK, Peters J, Wight J, de Zeeuw D, El Nahas M; European Kidney Institute.
    Am J Kidney Dis. 2008 Sep;52(3):434-43. 
  20. (-)-Epigallocatechin 3-O-gallate (EGCG)-induced apoptosis in normal rat kidney interstitial fibroblast (NRK-49F) cells.
    Miyamoto Y, Sano M, Haylor JL, El Nahas AM.
    J Toxicol Sci. 2008 Aug;33(3):367-70.
  21. Establishment of a European Network for Urine and Kidney Proteomics.
    Vlahou A, Schanstra J, Frokiaer J, El Nahas M, Spasovski G, Mischak H, Domon B, Allmaier G, Bongcam-Rudloff E, Attwood T; European Kidney and Urine Proteomics Network.
    J Proteomics. 2008 Oct 7;71(4):490-2. 
  22. Socioeconomic status and chronic kidney disease at presentation to a renal service in the United Kingdom.
    Bello AK, Peters J, Rigby J, Rahman AA, El Nahas M.
    Clin J Am Soc Nephrol. 2008 Sep;3(5):1316-23. 
  23. Prevalence of increased albumin excretion rate in young saudi adults.
    Abo-Zenah H, El-Benayan A, El Nahas AM.
    Nephron Clin Pract. 2008;108(2):c155-62. 
  24. Stem cell factor in a rat model of serum nephrotoxic nephritis.
    El Kossi MM, Haylor JL, Johnson TS, El Nahas AM.
    Nephron Exp Nephrol. 2008;108(1):e1-e10. 
  25. Stem cell factor in a rat model of serum nephrotoxic nephritis.
    El Kossi MM, Haylor JL, Johnson TS, El Nahas AM.
    Nephron Exp Nephrol. 2008;108(1)
  26. The contribution of combined crystalloid and colloid osmosis to fluid and sodium management in peritoneal dialysis.
    Freida P, Wilkie M, Jenkins S, Dallas F, Issad B.
    Kidney Int Suppl. 2008 Apr;(108):S102-11. 
  27. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.
    Messa P, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazão JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Wilkie M, Zani VJ, Molemans B, Carter D, Locatelli F.
    Clin J Am Soc Nephrol. 2008 Jan;3(1):36-45.
  28. Quality of life of living kidney donors: a single-center experience.
    Shrestha A, Shrestha A, Vallance C, McKane WS, Shrestha BM, Raftery AT.
    Transplant Proc. 2008 Jun;40(5):1375-7.
  29. De novo membranous nephropathy associated with donor-specific alloantibody.
    El Kossi M, Harmer A, Goodwin J, Wagner B, Shortland J, Angel C, McKane W.
    Clin Transplant. 2008 Jan-Feb;22(1):124-7.
  30. Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras/Raf signalling system.
    Parker E, Newby LJ, Sharpe CC, Rossetti S, Streets AJ, Harris PC, O'Hare MJ, Ong AC.
    Kidney Int. 2007 Jul;72(2):157-65.
  31. Involvement of hypoxia-inducible transcription factors in polycystic kidney disease.
    Bernhardt WM, Wiesener MS, Weidemann A, Schmitt R, Weichert W, Lechler P, Campean V, Ong AC, Willam C, Gretz N, Eckardt KU.
    Am J Pathol. 2007 Mar;170(3):830-42.
  32. Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation.
    Hamer RA, Chow CL, Ong AC, McKane WS.
    Transplantation. 2007 Jan 15;83(1):36-40.
  33. Endothelin B receptor blockade accelerates disease progression in a murine model of autosomal dominant polycystic kidney disease.
    Chang MY, Parker E, El Nahas M, Haylor JL, Ong AC.
    J Am Soc Nephrol. 2007 Feb;18(2):560-9.
  34. Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease.
    Johnson TS, Fisher M, Haylor JL, Hau Z, Skill NJ, Jones R, Saint R, Coutts I, Vickers ME, El Nahas AM, Griffin M.
    J Am Soc Nephrol. 2007 Dec;18(12):3078-88.
  35. Localization of matrix metalloproteinases and their inhibitors in experimental progressive kidney scarring.
    Ahmed AK, Haylor JL, El Nahas AM, Johnson TS.
    Kidney Int. 2007 Apr;71(8):755-63.
  36. Lack of effect of IGF-I on the glomerular filtration rate in non-diabetic patients with advanced chronic kidney disease.
    Kuan Y, Surman J, Frystyk J, El Nahas AM, Flyvbjerg A, Haylor JL.
    Growth Horm IGF Res. 2008 Nov 27. 
  37. The management of CKD: a look into the future.
    Khwaja A, El Kossi M, Floege J, El Nahas M.
    Kidney Int. 2007 Dec;72(11):1316-23. Epub 2007 Aug 15. 
  38. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes.
    Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, Nahas ME, Jaber BL, Jadoul M, Levin A, Powe NR, Rossert J, Wheeler DC, Lameire N, Eknoyan G.
    Kidney Int. 2007 Aug;72(3):247-59. 
  39. Obesity and diabetes in the developing world--a growing challenge.
    Hossain P, Kawar B, El Nahas M.
    N Engl J Med. 2007 Jan 18;356(3):213-5. 
  40. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials.
    Mann J, Kessler M, Villa G, Martinez-Castelao A, Feldt-Rasmussen B, Cruz J, Hörl WH, Mattin C, Praml C, Wilkie M.
    Clin Nephrol. 2007 Mar;67(3):140-8.
  41. The effect of body temperature in a rat model of renal ischemia-reperfusion injury.
    Delbridge MS, Shrestha BM, Raftery AT, El Nahas AM, Haylor JL.
    Transplant Proc. 2007 Dec;39(10):2983-5.
  42. Reduction of ischemia-reperfusion injury in the rat kidney by FTY720, a synthetic derivative of sphingosine.
    Delbridge MS, Shrestha BM, Raftery AT, El Nahas AM, Haylor JL.
    Transplantation. 2007 Jul 27;84(2):187-95.
  43. Mixing osmotic agents--two different approaches.
    Jenkins S, Wilkie M.
    Perit Dial Int. 2007 May-Jun;27(3):245-50.